Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Ready to Use Toxins
Description
Jolie Kaufman, a dermatologist involved in clinical research, discusses the introduction of ready-to-use (RTU) botulinum toxins, which are already available in regions like Asia and Europe but are not yet on the U.S. market. RTU toxins eliminate the need for reconstitution, providing advantages such as enhanced safety, consistent dosing, and time-saving benefits for practitioners. However, they come with drawbacks like limited dosing options and potential increased injection pain. Kaufman highlights various products set to arrive in the U.S., including liquid ABO, Neva botulinum toxin, and relabotulinum toxin, each backed by clinical studies suggesting early onset and comparable efficacy to existing treatments. She addresses challenges such as safety concerns from preparation errors and the unknown costs of these new products. The session underscores the need for head-to-head trials to accurately compare the efficacy of RTU toxins to current options, while also humorously reminding that not all wrinkles are undesirable.
View moreConclusions
- The introduction of ready-to-use (RTU) liquid botulinum toxins can enhance the safety, convenience, and consistency of administration for dermatologists.
- RTU toxins may reduce errors associated with reconstitution of botulinum toxin, which have been linked to adverse events.
- Clinical studies suggest that liquid formulations of botulinum toxins, such as liquid ABO and Nevo botulinum, may lead to a quicker onset of action compared to traditional powder forms.
- Liquid botulinum toxins are poised to offer advantages such as easier handling and potentially higher response rates in some clinical scenarios.
- While there are advantages to using ready-to-use liquid toxins, clinicians must consider dosing concentration and sting levels as potential drawbacks.
- The liquid formulation of botulinum toxins showed a similar safety profile to powdered formulations, with no significant new safety signals identified during clinical trials.
- Ongoing clinical studies and real-world applications will be crucial in establishing comparative effectiveness and safety between liquid and conventional botulinum toxins.
- Aesthet Surg J, Volume 38, Issue 2, February 2018, Pages 183-191, https://doi.org/10.1093/asj/sjw272
- Ascher et al. Aesthet Surg J, 2019.
- Aesthetic Surg J, Volume 42, Issue 3, March 2022, Pages 301-313.
- Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines. Plast Reconstr Surg. 2015 Mar;
- Chada et al. Ready to Use AbolbotulinumA solution vs. Powder botulinumtoxinA, J Cosm Dermatol, Sept, 2024.
- WooShun, Ho. Botulinum Toxin Innovation: From Powder to Liquid. Dermatol Surg, 2024.
- Dressler D, Adib Saberi F, Bigalke H. Botulinum toxin therapy: reduction of injection site pain by pH normalisation. J Neural Transm (Vienna). 2016
- Di Gregorio, C., Tretti-Clementoni, M., Belmontesi, M. et al. Real-World, Retrospective, Multicenter, Observational Study on the Use of the First Liquid AbobotulinumtoxinA in Italy. Dermatol Ther, 2023.